Last reviewed · How we verify
LP0113 aerosol spray
LP0113 aerosol spray is a corticosteroid used to reduce inflammation in the lungs.
LP0113 aerosol spray is a corticosteroid used to reduce inflammation in the lungs. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | LP0113 aerosol spray |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
It works by suppressing the immune system's response to inflammation, thereby reducing symptoms associated with respiratory conditions. The exact mechanism of action is not fully understood, but it is believed to involve the inhibition of phospholipase A2, a key enzyme in the inflammatory process.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oral thrush
- Hoarseness
- Cough
Key clinical trials
- A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LP0113 aerosol spray CI brief — competitive landscape report
- LP0113 aerosol spray updates RSS · CI watch RSS
- LEO Pharma portfolio CI